Alector licenses AL050 GCase therapy to Genentech for $1.27bn
Alector has signed an exclusive global licensing agreement with Genentech, granting the Roche subsidiary worldwide rights to develop and commercialise AL050, an investigational brain-penetrant glucocerebrosidase (GCase) enzyme replacement therapy targeting a key driver of neurodegeneration in Parkinson's disease. The deal, announced on 5 October 2026, delivers $100 million to Alector upfront and opens the door to a further $1.17 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on net sales.
AL050 pairs an Alector-engineered GCase with the company's proprietary Alector Brain Carrier (ABC) platform, a blood-brain barrier delivery technology designed to ferry therapeutics into the central nervous system. The engineered enzyme is optimised for greater activity and extended half-life; once inside the brain, it is intended to break down the lipids glucosylsphingosine and glucosylceramide, which accumulate in neurons when GCase activity is deficient and are associated with neurodegeneration. GCase deficiency is most pronounced in carriers of GBA1 mutations, though the therapy is being positioned for a broader patient population.
The deal
Under the terms of the agreement, Genentech takes on full responsibility for development, regulatory affairs, manufacturing, and commercialisation across all indications. Alector retains ownership of the ABC platform and full rights to apply it across its wholly owned pipeline, a carve-out that materially limits the deal's reach into Alector's broader portfolio.
Arnon Rosenthal, chief executive of Alector, said that no approved therapy currently addresses the underlying GCase enzyme deficiency in Parkinson's disease, and described the pairing of an engineered enzyme with ABC as the dual solution to a dual challenge: optimal enzyme engineering and effective CNS delivery. Boris Zaïtra, head of Roche corporate business development, framed the partnership within Roche's stated aim of delaying or halting Parkinson's progression to preserve patient independence.
Alector said the upfront proceeds extend its cash runway into 2029, giving the company resources to advance AL137, its brain-enabled anti-amyloid beta antibody, through multi-cohort clinical data in Alzheimer's patients, and to move its tau siRNA and alpha-synuclein siRNA programmes through IND-enabling studies to IND filings. A scientific webinar covering those wholly owned assets is scheduled for 13 October 2026.
Market context
GBA1-associated Parkinson's disease is an active target for the industry, with several approaches in development including small-molecule GCase activators and gene therapies. The enzyme replacement route is less commonly pursued in the CNS context, primarily because delivering large protein molecules across the blood-brain barrier has historically been a significant obstacle. Alector's ABC platform is its proposed solution, though the approach remains preclinical for AL050 and has yet to generate clinical proof-of-concept data.
Roche and Genentech have long-standing interests in neurodegeneration, spanning amyloid-targeting antibodies for Alzheimer's disease and Parkinson's-related assets. The AL050 licence fits a broader strategy of in-licensing mechanistically distinct programmes at the preclinical or early clinical stage, spreading portfolio risk across multiple biological hypotheses. For Alector, the structure of the deal is notable: retaining ABC means the company keeps the commercial and scientific optionality of its platform even as it monetises one of its programmes. How the therapy performs in first-in-human studies will be watched closely given the unmet need in GBA1 carriers and the absence of any approved GCase-directed treatment in neurodegenerative disease.